Skip to main
RLAY

RLAY Stock Forecast & Price Target

RLAY Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 44%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of potential life-changing therapies in precision oncology and genetic disease. Their Dynamo platform integrates cutting-edge computational and experimental approaches, making them a leader in drug discovery. Recent data shows promising potential for their candidates in both front-line and later-line treatments, with good tolerability and potential to improve on negative psychological impacts associated with IV therapy. The company's well-balanced patient demographics and progress in their clinical trials demonstrate a strong potential for future success.

Bears say

Relay Therapeutics is currently undergoing clinical trials for various precision oncology and genetic disease targets, which presents inherent risks for the company's drug development process. Additionally, the company's potential for regulatory and commercial success is uncertain, and it may face competition from larger companies in the cancer therapeutic industry. Furthermore, the company is likely to seek additional equity financing, creating dilution risk for existing shareholders.

RLAY has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 44% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Relay Therapeutics, Inc. (RLAY) Forecast

Analysts have given RLAY a Buy based on their latest research and market trends.

According to 9 analysts, RLAY has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Relay Therapeutics, Inc. (RLAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.